Direct cell killing by suicide genes

Cancer and Metastasis Reviews

Volumn 15, Issue 3, 1996, Pages 301-316

  Martin, L A ^a   Lemoine, N R ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

gene therapy; suicide genes; transcriptional control

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ALANINE; ALKALINE PHOSPHATASE; AMYGDALIN; BETA GLUCOSIDASE; BETA GLUCURONIDASE; BETA LACTAMASE; CARBOXYPEPTIDASE A; CARBOXYPEPTIDASE G2; CEPHALOSPORIN DERIVATIVE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOSINE DEAMINASE; ENZYME; EPIRUBICIN GLUCURONIDE; ETOPOSIDE; FLUCYTOSINE; GANCICLOVIR; IFOSFAMIDE; METHOTREXATE; MITOMYCIN; NITROREDUCTASE; PRODRUG; THYMIDINE KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE OXIDASE;

APOPTOSIS; CANCER; CELL KILLING; DRUG ACTIVATION; GENE THERAPY; PRIORITY JOURNAL; REVIEW; SUICIDE GENE;

EID: 0029847212     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00046344     Document Type: Review

References (76)

1. Sikora K: Gene therapy for cancer. Trends Biotechnol 11(5): 197-201, 1993
2. Bishop JM: Molecular themes in oncogenesis. Cell 64: 235-248, 1991
3. Culver KW, Blaese RM: Gene therapy for cancer. TIG 10 (5): 174-178, 1994
4. Mullen CA: Metabolic suicide genes in gene therapy. Pharmac Ther 63: 199-207, 1994
5. Connors TA: The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther 2: 702-709, 1995
6. Moolten FL, Wells JM: Curability of tumours bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natn Cancer Inst 82: 297-300, 1990
7. Abe A, Takeo T, Emi N, Tanimoto M, Ueda R, Yee JK, Friedman T, Saito H: Transduction of a drug sensitive toxic gene into human leukemia cell lines with a novel retroviral vector. Proc Soc Exp Biol Med 203: 354-359, 1993
8. Reid R, Mar EC, Huang ES, Topal MD: Insertion and extension of acyclic, dideoxy and ara nucleotides by herpesviridae, human alpha and human beta polymerases. A unique inhibition mechanism for 9-(1,3-dihydroxy-2-propoxymethyl) guanine triphosphate. J Biol Chem 263: 3898-3904, 1988
9. Mar EC, Chiou JF, Cheng YC, Huang ES: Inhibition of cellular DNA polymerase alpha and human cytomegalovirus-induced DNA polymerase by triphosphates of 9-(2-hydroxyethoxymethyl) guanine and 9-(1,3-dihydroxy-2-propoxymethyl) guanine. J Virol 53: 776-780, 1985
10. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR: Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 54: 6223-6234, 1994
11. Bi WL, Parysek LM, Warnick R, Stambrook PJ: In vitro evidence that metabolic cooperation in responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 4: 725-732, 1993
12. Danielsen S, Kilstrup M, Barilla K, Jochimsen B, Neuhard J: Characterization of the Escherichia coli codBA operon encoding cytosine permease and cytosine deaminase. Molec Microbiol 6: 1335-1344, 1992
13. Pinedo HM, Peters GFJ: Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 6: 1653-1644, 1988
14. Van der Wilt CL, Pinedo HM, Smid K, Cloos J, Noordhuis P, Peters GJ: Effect of folinic acid on fluorouracil activity and expression of thymidylate synthase. Semin Oncol 19: 16-25, 1992
15. Huber BE, Richards CA, Krenitsky TA: Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA 88: 8039-8043, 1991
16. Knox RJ, Friedlos F, Boland MP: The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metastasis Rev 12: 195-212, 1993
17. Chen L, Waxman DJ: Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: Development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 55: 581-589, 1995
18. Wei MX, Tamiya T, Rhee RJ, Breakefield XO, Chiocca EA: Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res 1: 1171-1177, 1995
19. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfeld EH, Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552, 1992
20. Miyao Y, Shimizu K, Moriuchi S, Yamada M, Nakahira K, Nakajima K, Nakao J, Kuriyama S, Tsujii T, Mikoshiha K: Selective expression of foreign genes in glioma cells: use of the mouse myelin basic protein gene promoter to direct toxic gene expression. J Neurosci Res 36(4): 472-479, 1993
21. Battini JL, Heard JM, Danos O: Receptor choice determinants in the envelope glycoproteins of amphotrophic, xenotrophic and polytrophic murine leukemia viruses. J Virol 66: 1468-1475, 1992
22. Ott D, Rein A: Basis for receptor specificity of non-ecotropic murine leukemia virus surface glycoprotein gp70SU. J Virol 66: 4632-4636, 1992
23. Salmons B, Gunzberg WH: Targeting of retroviral vectors for gene therapy. Hum Gen Ther 4: 129-141, 1993
24. Valsesia-Wittmann S, Drynda A, Deleage G, Aumailley M, Heard JM, Danos O, Verdier G, Cosset FL: Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J Virol 68: 4609-4619, 1994
25. Russell SJ, Hawkins RE, Winter G: Retroviral vectors displaying functional antibody fragments. NAR 21: 1081-1085, 1993
26. Chu T-HT, Martinez I, Sheay WC, Dornburg R: Cell targeting with retroviral vector particles containing antibody-envelope fusions. Gene Ther 1: 292-299, 1994
27. Cossett FL, Morling FJ, Takeuchi Y, Weiss RA, Collins MKL, Russell SJ: Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol 69(10): 6314-6322, 1995
28. Valsesia-Wittmann S, Morling FJ, Nilson BHK, Takeuchi Y, Russell SJ, Cosset FL: Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N-terminus of moloney murine leukemia virus SU. J Virol 70: 2059-2064, 1996
29. Nilson BHK, Morling FS, Cosset FL, Russel SJ: Targeting of retroviral vectors through protease-substrate interactions. Gene Ther 3: 280-286, 1996
30. Michael SI, Hong JS, Curiel DT, Engler JA: Addition of a short peptide ligand to the adenovirus fibre protein. Gene Ther 2: 660-668, 1995
31. Wickham TJ, Carrion ME, Kovesdi I: Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor -specific peptide motifs. Gene Ther 2: 750-756, 1995
32. Maxwell IH, Glode LM, Maxwell F: Expression of the diptheria toxin A-chain coding sequences under the control of promoters and enhancers from immunoglobulin genes as a means of directing toxicity to B-lymphoid cells. Cancer Res 51: 4299-4304, 1991
33. Kuriyama S, Yoshikawa M, Ishizaka S, Tsujii T, Ikenaka K, Kagawa T, Morita N, Mikoshiba K: A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector. Cell Struct Func 16(6): 503-510, 1991
34. Vile RG, Hart IR: In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 53: 962-967, 1993
35. Vile RG, Hart IR: Use of tissue specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct injection of DNA. Cancer Res 53: 3860-3864, 1993
36. Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR: Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther 1: 170-175, 1994
37. Grosschedl R, Baltimore D: Cell-type specificity of immunoglobulin gene expression is regulated by at least three DNA sequence elements. Cell 41: 885-897, 1985
38. Curiel T, Nicot D, Maxwell F, Maxwell I, Wagner E, Curiel D: Immunoglobulin-regulated diptheria toxin A-chain gene delivered in vitro and in vivo by adenovirus-DNA-polylysine conjugates as gene therapy for B-cell cancers. Cancer Gene Ther (Abstract) 1(Suppl 1): 3, 1993/1994
39. Richards CA, Huber BB: Generation of a transgenic model for retrovirus-mediated gene therapy for hepatocellular carcinoma is thwarted by lack of transgene expression. Hum Gene Ther 4: 143-150, 1993
40. Kluppel M, Beermann F, Puppert S, Schmid E, Hummler E, Schutz G: The mouse tyrosinase promoter is sufficient for expression in melanocytes and in the pigmented epithelium of the retina. Proc Natl Acad Sci USA 88: 3777-3781, 1991
41. Gullick WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Brit Med Bull 47: 87-98, 1991
42. Hollywood DP, Hurst H: A novel transcription factor, OB21, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J 12: 2369-2375, 1993
43. Bosher JM, Williams T, Hurst HC: The developmentally regulated transcription factor AP-2 is involved in c-erb B-2 overexpression in human mammary carcinoma. Proc Natl Acad Sci USA 92: 744-747, 1995
44. Fujita K, Sugaya S, Ishii S, Tanaka K: Specific expression of Pseudomonas exotoxin in tumour cells promoted by myc binding sequence. Cancer Gene Ther 1 (suppl 1): 3, 1993/ 1994
45. Richards CA, Austin EA, Huber BE: Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 6: 881-893, 1995
46. Austin EA, Huber BH: A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol 43: 380-387, 1993
47. Huber BE, Austin EA, Good SS, Knick VC, Tibbels S, Richards CA: In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 53: 4619-4626
48. Richards CA, Wolberg AS, Huber BE: The transcriptional control region of the human carcinoembryonic antigen gene: DNA sequence and homology studies. DNA sequence 4: 185-196, 1993
49. Huber BE, Austin EA, Richards CA, Davis ST, Good SS: Metabolism of 5-fluorocytosine to 5-fluorouracilin human colorectal tumour cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 91: 8302-8306, 1994
50. Schrewe H, Thompson J, Bona M, Hefta LJF, Maruya A, Hassauer M, Shively JE, Von Kleist S, Zimmerman W: Cloning of the complete gene for carcinoembryonic antigen: Analysis of its promoter indicates a region conveying cell-type specific expression. Mol Cell Biol 10: 2738-2748, 1990
51. Su H, Chang JC, Xu SM, Kan YW: Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther 7: 463-470, 1996
52. Ring CJA, Harris JD, Hurst HC, Lemoine NR: Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Gene Ther, in press, 1996
53. Vile RG, Diaz RM, Miller N, Mitchell S, Russell SJ: Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter. Virology 214: 307-313, 1995
54. Moolten FS, Wells JM, Mroz PJ: Multiple transduction as a means of preserving ganciclovir chemosensitivity in sarcoma cells carrying retrovirally transduced herpes thymidine kinase genes. Cancer Lett 64: 257-263, 1992
55. Freeman S, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN: The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53: 5274-5283, 1993
56. Mullen CA, Coale MM, Lowe R, Blaese RM: Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res 54: 1503-1506, 1994
57. Chen PL, Chen Y, Bookstein R, Lee WH: Genetic mechanisms of tumor suppression by the human p53 gene. Science 250: 1576-1580, 1990
58. Takahashi T, Carbone D, Takahashi T, Nau MM, Hilda T, Linnoila I, Ueda R, Minna JD: Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 52: 2340-2343, 1992
59. Wills KN, Maneval DC, Menzel P, Harris MP, Sutjipto S, Vaillancourt M-T, Huang W-M, Johnson DE, Anderson SC, Wen SF, Bookstein R, Shepard HM, Gregory RJ: Development of characterisation of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 5: 1079-1088, 1994
60. Clayman GL, El-Nagger AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, Liu TJ: In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 55: 1-6, 1995
61. Yang C, Cirielli C, Capogrossi MC, Passaniti A: Adenovirus-mediated wild-type expression induces apoptosis and suppresses tumorigenesis of prostatic tumour cells. Cancer Res 55: 4210-4213, 1995
62. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993
63. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 36: 701-704, 1993
64. Waga S, Hannon GJ, Beach D, Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578, 1994
65. 1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994
66. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimers in vivo with a conserved homologue, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993
67. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Hoffman B, Lieberman D, Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax in gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994
68. Kiefer MC, Brauwer MJ, Powers VC, Wu JJ, Umansky SR, Tomei LD, Barr PJ: Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 374: 736-739, 1995
69. Chittenden T, Flemington C, Houghton AB, Ebb RG, Gallo GJ, Elangovan B, Chinnadurai G, Lutz R: A conserved domain in Bak. is distinct from BH1 and BH2, mediates cell death and protein binding functions. EMBO 14(22): 5589-5596, 1995
70. Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL, Anderson WF: Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 4: 39-69, 1993
71. Klatzmann D, Philippen J, Valery CA, Bensimon G, Salzmann J-L: Clinical protocol. Gene therapy for glioblastoma in adult patients: Safety and efficacy evaluation of an in situ injection of recombinant retroviruses producing cells carrying the thymidine kinase gene of the herpes simplex type 1 virus, to be followed with the administration of ganciclovir. Hum Gene Ther 7: 109-126, 1996
72. Riddell SR, Greenberg PD, Overell RW, Loughran TP, Gilbert MJ, Lupton SD, Agosti J, Scheeler S, Coombs RW, Corey L: Phase 1 study of cellular adoptive immunotherapy using genetically modified CD8 + HIV - specific T cells for HIV seropositive patients undergoing allogenic bone marrow transplant. Hum Gene Ther 3: 319-338, 1992
73. Eck SL, Alavi JB: Treatment of advanced CNS malignancy with the recombinant Adenovirus H5.020RSVTK: A Phase 1 trial. Hum Gene Ther 6(4): 509-512, 1995
74. Albelda SM: Treatment of advanced mesothelioma with recombinant adenovirus H5.020RSVTK: A Phase 1 trial. Hum Gene Ther 6(4): 509-514, 1995
75. Grossman RG, Woo SLC: Phase I study of adenoviral vector delivery of the HSV-TK gene and the intravenous administration of ganciclovir in adults with malignant tumors of the central nervous system. Hum Gene Ther 6(8): 1090-1093, 1995
76. Miller N, Vile R: Targeted vectors for gene therapy. FASEB J 9: 190-199, 1995